Medical outcomes of glaucoma therapy from a nationwide representative survey

Clinical Drug Investigation

Volumn 24, Issue 6, 2004, Pages 343-352

  Denis, Philippe ^a   Lafuma, Antoine ^b   Berdeaux, Gilles ^c  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CEMKA EVAL   (France)

^c Alcon France ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; PROSTAGLANDIN;

ADULT; AGED; COMORBIDITY; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DISEASE COURSE; DRUG USE; FEMALE; FRANCE; GLAUCOMA; HEALTH SURVEY; HUMAN; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; OPHTHALMOLOGY; OPTIC NERVE; PATIENT SATISFACTION; PRESCRIPTION; PRIORITY JOURNAL; RANK SUM TEST; REVIEW; RISK FACTOR; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL FIELD;

EID: 3042741190     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200424060-00004     Document Type: Review

References (33)

1. David R, Livingston DG, Lunz MH. Ocular hypertension: a long term follow-up of treated and untreated patients. Br J Ophthalmol 1977; 61: 668-74
2. Epstein DL, Krug JH, Hertzmark E, et al. A long-term clinical trial of timolol therapy versus no treatment in the management of glaucoma suspects. Ophthalmology 1989; 96: 1460-7
3. Gaasterland DE, Ederer F, Sullivan EK, et al. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race: seven-year results. Ophthalmology 1998; 105: 1146-64
4. Heijl A, Bengtsson B. Long-term effects of timolol therapy in ocular hypertension: a double-masked, randomized trial. Graefes Arch Clin Exp Ophthalmol 2000; 238: 877-83
5. Kass MA, Gordon MO, Hoff MR, et al. Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals: a randomized, double masked, long term clinical trial. Arch Ophthalmol 1989; 107: 1590-8
6. Kass MA, Heuer DK, Higginbotham EJ, et al. for the Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-13
7. Shin DJ, Kolker AE, Kass MA, et al. Long-term epinephrine therapy of ocular hypertension. Arch Ophthalmol 1976; 94: 2059-60
8. Shulzer M, Drance SM, Douglas GR. A comparison of treated and untreated glaucoma suspects. Ophthalmology 1991; 98: 301-7
9. Van Veldhuisen PC, Dally LG, Gaasterland DE, et al. The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups. Am J Ophthalmol 2001; 123: 311-20
10. Leske MV, Heijl A, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Acta Ophthalmol Scand 2002; 120: 1268-79
11. AGIS Investigators. The Advanced Glaucoma Intervention study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology 1998; 105: 1146-64
12. Lichter PR, Musch DC, Gillepsie BW, et al. Interim clinical outcome in the Collaborative Initial Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001; 108: 1943-53
13. Hjelmgren J, Berggren F, Andersson D. Health economics guidelines: similarities, differences and some implications. Value Health 2001; 4: 225-50
14. Strom LB. Pharmacoepidemiology. 2nd ed. Chichester, England: John Wiley, 1994
15. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcome in the Collaborative Initial Treatment Study comparing initial treatment randomised to medications or surgery. Ophthalmology 2001; 108 (11): 1948-53
16. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS). 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology 1998; 105 (7): 1146-64
17. Leske MV, Heijl A, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Acta Ophthalmol 2002; 120: 1268-79
18. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, et al. for the Ocular Hypertension Treatment Study group. The Ocular Hypertension Treatment Study: a randomised trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-13
19. Calissendorff BM. Costs of medical and surgical treatment of glaucoma. Acta Ophthalmol Scand 2001; 79: 286-8
20. Jonsson B, Krieglstein G. Primary open-angle glaucoma: differences in international treatment patterns and costs. Oxford: Isis Medical Media, 1999
21. Kobelt G, Jonsson L, Gerdtham U, et al. Direct costs of glaucoma management following initiation of medical therapy: a simulation model based on an observational study of glaucoma treatment in Germany. Graefes Arch Clin Exp Ophthalmol 1998; 236: 811-21
22. Kobelt G, Jonsson L. Modeling cost of treatment with new topical treatments for glaucoma: results from France and the United Kingdom. Int J Technol Assess Health Care 1999; 15: 207-19
23. Kobelt-Nguyen G, Gerdtham UG. Alm A. Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States. J Glaucoma 1998; 7: 95-104
24. Oostenbrink JB, Rutten-van Molken MP, Opdenoordt TS. The treatment of newly diagnosed patients with glaucoma or with ocular hypertension in The Netherlands: an observational study of costs and initial treatment success based on retrospective chart review. Doc Ophthalmol 1999; 98: 285-99
25. Oostenbrink JB, Rutten-van Molken MP, Sluyter-Opdenoordt TS. Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands. J Glaucoma 2001; 10: 184-91
26. Rouland JF, Peigne G, Sellem E, et al. An observational, retrospective two-year cost study in primary open-angle glaucoma and ocular hypertension in newly diagnosed patients. J Fr Ophtalmol 2001; 24: 233-43
27. Association des Epidemiologistes de Langue Francaise. Déontologie et bonnes pratiques en épidémiologie, recommandations de l'Association des Epidémiologistes de Langue Francaise, Saint-Maurice, France, 1998: adelf@st-maurice.inserm.fr
28. Liste des Prescripteurs. Code. TVF. Cegedim, Boulogne-Billancourt, France
29. Anderson DR, Patella VM. Automated static perimetry, second edition. Mosby, St Louis (MI): 1999
30. Jonas JB, Budde WM. Is the nasal optic disc sector important for morphometric glaucoma diagnosis? Br J Ophthalmol 2002; 86: 1232-5
31. Stewart WC, Connor AB, Rogers GM. Correlation of pattern discrimination perimetry to the optic disc and visual field in ocular hypertensive and chronic open-angle glaucoma patients. Int Ophthalmol 1995; 19: 101-7
32. Chauhan BC, Drance SM, Douglas GR. The use of visual field indices in detecting changes in the visual field in glaucoma. Invest Ophthalmol Vis Sci 1990; 31: 512-20
33. Smith SD, Katz J, Quigley HA. Analysis of progressive change in automated visual fields in glaucoma. Invest Ophthalmol Vis Sci 1996; 37: 1419-28